Patents by Inventor Simak Ali
Simak Ali has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11566029Abstract: Certain pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds that inhibit cycline dependent kinase (CDK) (e.g., CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, CDK13, etc.) are disclosed. Pharmaceutical compositions comprising these compounds, and the use of these compounds and compositions to inhibit CDK; to treat disorders associated with CDK such as those arising from an inappropriate activity, mutation, overexpression, or upstream pathway activation of CDK; or disorders that are ameliorated by the inhibition of CDK; proliferative disorders; cancer; viral infections; neurodegenerative disorders; ischaemia; renal diseases; and cardiovascular disorders are also disclosed. Optionally, the treatment further comprises simultaneous or sequential treatment with a further active agent, e.g., an aromatase inhibitor, an anti-estrogen, a Her2 blocker, a cytotoxic chemotherapeutic agent, etc.Type: GrantFiled: February 15, 2021Date of Patent: January 31, 2023Assignees: IP2IPO Innovations Limited, Emory University, Cancer Research Technology LimitedInventors: Alexander Bondke, Sebastian Kroll, Anthony Barrett, Matthew Fuchter, Brian Slafer, Simak Ali, Charles Coombes, James Patrick Snyder
-
Publication number: 20210253583Abstract: Certain pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds that inhibit cycline dependent kinase (CDK) (e.g., CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, CDK13, etc.) are disclosed. Pharmaceutical compositions comprising these compounds, and the use of these compounds and compositions to inhibit CDK; to treat disorders associated with CDK such as those arising from an inappropriate activity, mutation, overexpression, or upstream pathway activation of CDK; or disorders that are ameliorated by the inhibition of CDK; proliferative disorders; cancer; viral infections; neurodegenerative disorders; ischaemia; renal diseases; and cardiovascular disorders are also disclosed. Optionally, the treatment further comprises simultaneous or sequential treatment with a further active agent, e.g., an aromatase inhibitor, an anti-estrogen, a Her2 blocker, a cytotoxic chemotherapeutic agent, etc.Type: ApplicationFiled: February 15, 2021Publication date: August 19, 2021Inventors: Alexander BONDKE, Sebastian KROLL, Anthony BARRETT, Matthew FUCHTER, Brian SLAFER, Simak ALI, Charles COOMBES, James Patrick SNYDER
-
Patent number: 10927119Abstract: Certain pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds that inhibit cycline dependent kinase (CDK) (e.g., CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, CDK13, etc.) are disclosed. Pharmaceutical compositions comprising these compounds, and the use of these compounds and compositions to inhibit CDK; to treat disorders associated with CDK such as those arising from an inappropriate activity, mutation, overexpression, or upstream pathway activation of CDK; or disorders that are ameliorated by the inhibition of CDK; proliferative disorders; cancer; viral infections; neurodegenerative disorders; ischaemia; renal diseases; and cardiovascular disorders are also disclosed. Optionally, the treatment further comprises simultaneous or sequential treatment with a further active agent, e.g., an aromatase inhibitor, an anti-estrogen, a Her2 blocker, a cytotoxic chemotherapeutic agent, etc.Type: GrantFiled: September 4, 2019Date of Patent: February 23, 2021Assignees: IP2IPO Innovations Limited, Emory University, Cancer Research Technology LimitedInventors: Alexander Bondke, Sebastian Kroll, Anthony Barrett, Matthew Fuchter, Brian Slafer, Simak Ali, Charles Coombes, James Patrick Snyder
-
Publication number: 20200055862Abstract: Certain pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds that inhibit cycline dependent kinase (CDK) (e.g., CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, CDK13, etc.) are disclosed. Pharmaceutical compositions comprising these compounds, and the use of these compounds and compositions to inhibit CDK; to treat disorders associated with CDK such as those arising from an inappropriate activity, mutation, overexpression, or upstream pathway activation of CDK; or disorders that are ameliorated by the inhibition of CDK; proliferative disorders; cancer; viral infections; neurodegenerative disorders; ischaemia; renal diseases; and cardiovascular disorders are also disclosed. Optionally, the treatment further comprises simultaneous or sequential treatment with a further active agent, e.g., an aromatase inhibitor, an anti-estrogen, a Her2 blocker, a cytotoxic chemotherapeutic agent, etc.Type: ApplicationFiled: September 4, 2019Publication date: February 20, 2020Inventors: Alexander Bondke, Sebastian Kroll, Anthony Barrett, Matthew Fuchter, Brian Slafer, Simak Ali, Charles Coombes, James Patrick Snyder
-
Patent number: 10414772Abstract: Certain pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds that inhibit cycline dependent kinase (CDK) (e.g., CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, CDK13, etc.) are disclosed. Pharmaceutical compositions comprising these compounds, and the use of these compounds and compositions to inhibit CDK; to treat disorders associated with CDK such as those arising from an inappropriate activity, mutation, overexpression, or upstream pathway activation of CDK; or disorders that are ameliorated by the inhibition of CDK; proliferative disorders; cancer; viral infections; neurodegenerative disorders; ischaemia; renal diseases; and cardiovascular disorders are also disclosed. Optionally, the treatment further comprises simultaneous or sequential treatment with a further active agent, e.g., an aromatase inhibitor, an anti-estrogen, a Her2 blocker, a cytotoxic chemotherapeutic agent, etc.Type: GrantFiled: March 30, 2018Date of Patent: September 17, 2019Assignees: Imperial Innovations Limited, Emory University, Cancer Research Technology LimitedInventors: Alexander Bondke, Sebastian Kroll, Anthony Barrett, Matthew Fuchter, Brian Slafer, Simak Ali, Charles Coombes, James Patrick Snyder
-
Publication number: 20180273540Abstract: Certain pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds that inhibit cycline dependent kinase (CDK) (e.g., CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, CDK13, etc.) are disclosed. Pharmaceutical compositions comprising these compounds, and the use of these compounds and compositions to inhibit CDK; to treat disorders associated with CDK such as those arising from an inappropriate activity, mutation, overexpression, or upstream pathway activation of CDK; or disorders that are ameliorated by the inhibition of CDK; proliferative disorders; cancer; viral infections; neurodegenerative disorders; ischaemia; renal diseases; and cardiovascular disorders are also disclosed. Optionally, the treatment further comprises simultaneous or sequential treatment with a further active agent, e.g., an aromatase inhibitor, an anti-estrogen, a Her2 blocker, a cytotoxic chemotherapeutic agent, etc.Type: ApplicationFiled: March 30, 2018Publication date: September 27, 2018Inventors: Alexander BONDKE, Sebastian KROLL, Anthony BARRETT, Matthew FUCHTER, Brian SLAFER, Simak ALI, Charles COOMBES, James Patrick SNYDER
-
Patent number: 9932344Abstract: Certain pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds that inhibit cycline dependent kinase (CDK) (e.g., CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, CDK13, etc.) are disclosed. Pharmaceutical compositions comprising these compounds, and the use of these compounds and compositions to inhibit CDK; to treat disorders associated with CDK such as those arising from an inappropriate activity, mutation, overexpression, or upstream pathway activation of CDK; or disorders that are ameliorated by the inhibition of CDK; proliferative disorders; cancer; viral infections; neurodegenerative disorders; ischaemia; renal diseases; and cardiovascular disorders are also disclosed. Optionally, the treatment further comprises simultaneous or sequential treatment with a further active agent, e.g., an aromatase inhibitor, an anti-estrogen, a Her2 blocker, a cytotoxic chemotherapeutic agent, etc.Type: GrantFiled: February 20, 2015Date of Patent: April 3, 2018Assignees: Cancer Research Technology Limited, Imperial Innovations Limited, Emory UniversityInventors: Alexander Bondke, Sebastian Kroll, Anthony Barrett, Matthew Fuchter, Brian Slafer, Simak Ali, Charles Coombes, James Patrick Snyder
-
Publication number: 20160362410Abstract: The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain pyrazolo[1,5-a]pyrimidine-5,7-diamine compounds (referred to herein as “PPDA compounds”) that, inter alia, inhibit (e.g., selectively inhibit) CDK (e.g., CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, CDK13, etc.).Type: ApplicationFiled: February 20, 2015Publication date: December 15, 2016Inventors: Alexander BONDKE, Sebastian KROLL, Anthony BARRETT, Matthew FUCHTER, Brian SLAFER, Simak ALI, Charles COOMBES, James Patrick SNYDER
-
Publication number: 20120077270Abstract: A method for suppressing the expression of a selected gene in a cell, the method comprising introducing into the cell a molecule comprising (1) a nucleic acid binding portion which binds to a site or associated with the selected gene which site is present in a genome and (2) an expression repressor portion, wherein the nucleic acid binding portion comprises an oligonucleotide or oligonucleotide mimic or analogue, and wherein the repressor portion comprises a polypeptide or peptidomimetic. Molecules for use in the methods of the invention are provided. The repressor may be a portion of a histone deacetylase or DNA methylase or polypeptide capable of recruiting a histone deacetylase or DNA methylase.Type: ApplicationFiled: October 3, 2011Publication date: March 29, 2012Applicant: IMPERIAL COLLEGE INNOVATIONS LIMITEDInventors: Stephen Hart, Simak Ali, Boris Tumi PuFong, Andrew C.G. Porter, Laki Buluwela, Satu Vainikka, John David Jenkinson, Patrick Kanda
-
Patent number: 8067424Abstract: This invention provides a class of compounds which are useful for specifically inhibiting cyclin-dependent kinases. This class of compounds finds use in treating diseases resulting from inappropriate activity of cyclin-dependent kinases, including cancer, viral infections (e.g., HIV) neurodegenerative disorders (e.g. Alzheimer's disease), and cardiovascular disorders (e.g. atherosclerosis). Moreover, certain members of this class are particularly useful for inhibiting cyclin-dependent kinase 7 and are especially useful for the treatment of breast cancer.Type: GrantFiled: December 4, 2009Date of Patent: November 29, 2011Assignees: Emory University, Imperial College of Science and TechnologyInventors: Ashutosh S. Jogalekar, James P. Snyder, Dennis C. Liotta, Anthony G. M. Barrett, Raoul Charles Dalmedo Stuart Coombes, Simak Ali, Aleksandra Siwicka, Jan Brackow, Bodo Scheiper
-
Publication number: 20110189669Abstract: The current invention provides a method for aiding in the assessment of prostate cancer (including metastatic prostate cancer) and/or benign prostate hyperplasia in a patient, wherein the method comprises the step of determining the level of Glycine N-methyltransferase (GNMT) nucleic acid and/or protein in a sample from the patient. The invention also provides compounds that target Glycine N-methyltransferase (GNMT) protein and/or nucleic acid for use in treating prostate cancer. Also provided are screening methods for selecting a compound considered to be useful in treating prostate cancer, comprising the steps of determining the ability of a test compound to reduce GNMT activity and selecting a compound that reduces GNMT activity. The invention also provides methods for aiding in the diagnosis of prostate cancer in a patient comprising obtaining a sample from the patient and assessing said sample for a marker of GNMT activity.Type: ApplicationFiled: June 19, 2009Publication date: August 4, 2011Applicant: IMPERIAL INNOVATIONS LIMITEDInventors: Laki Buluwela, Jonathan Waxman, Simak Ali, Sarah Ngan
-
Publication number: 20100261683Abstract: This invention provides a class of compounds which are useful for specifically inhibiting cyclin-dependent kinases. This class of compounds finds use in treating diseases resulting from inappropriate activity of cyclin-dependent kinases, including cancer, viral infections (e.g., HIV) neurodegenerative disorders (e.g. Alzheimer's disease), and cardiovascular disorders (e.g. atherosclerosis). Moreover, certain members of this class are particularly useful for inhibiting cyclin-dependent kinase 7 and are especially useful for the treatment of breast cancer.Type: ApplicationFiled: December 4, 2009Publication date: October 14, 2010Inventors: Ashutosh S. Jogalekar, James P. Snyder, Dennis C. Liotta, Anthony G.M. Barrett, RCDS Coombes, Simak Ali, Aleksandra Siwicka, Jan Brackow, Bodo Scheiper
-
Publication number: 20090082250Abstract: A method for suppressing the expression of a selected gene in a cell the method comprising introducing into the cell a molecule comprising (1) a nucleic acid binding portion which binds to a site or associated with the selected gene which site is present in a genome and (2) an expression repressor portion, wherein the nucleic acid binding portion comprises an oligonucleotide or oligonucleotide mimic or analogue, and wherein the repressor portion comprises a polypeptide or peptidomimetic. Molecules for use in the methods of the invention are provided. The repressor may be a portion of a histone deacetylase or DNA methylase or polypeptide capable of recruiting a histone deacetylase or DNA methylase.Type: ApplicationFiled: May 13, 2008Publication date: March 26, 2009Applicant: IMPERIAL COLLEGEINNOVATIONS LIMITEDInventors: Stephen Hart, Simak Ali, Boris Tumi PuFong, Andrew C. G. Porter, Laki Buluwela, Satu Vainikka, John David Jenkinson, Patrick Kanda
-
Publication number: 20080026985Abstract: A method of suppressing the expression of a selected gene in a eukaryotic cell the method comprising introducing into the cell (a) a polypeptide comprising a DNA binding portion which binds to a site at or associated with the selected gene which site is present in a plant or animal genome and a chromatin inactivation portion, or (b) a polynucleotide encoding said polypeptide.Type: ApplicationFiled: February 28, 2007Publication date: January 31, 2008Applicant: Imperial Innovations LimitedInventors: Lakjaya Buluwela, Simak Ali
-
Patent number: 7202025Abstract: A method of suppressing the expression of a selected gene in a eukaryotic cell the method comprising introducing into the cell (a) a polypeptide comprising a DNA binding portion which binds to a site at or associated with the selected gene which site is present in a plant r animal genome and a chromatin inactivation portion, or (b) a polynucleotide encoding said polypeptide.Type: GrantFiled: June 28, 2000Date of Patent: April 10, 2007Assignee: Gene Expression Technologies LimitedInventors: Lakjaya Buluwela, Simak Ali
-
Publication number: 20050136040Abstract: A method for suppressing the expression of a selected gene in a cell the method comprising introducing into the cell a molecule comprising (1) a nucleic acid binding portion which binds to a site or associated with the selected gene which site is present in a genome and (2) an expression repressor portion, wherein the nucleic acid binding portion comprises an oligonucleotide or oligonucleotide mimic or analogue, and wherein the repressor portion comprises a polypeptide or peptidomimetic. Molecules for use in the methods of the invention are provided. The repressor may be a portion of a histone deacetylase or DNA methylase or polypeptide capable of recruiting a histone deacetylase or DNA methylase.Type: ApplicationFiled: April 8, 2004Publication date: June 23, 2005Applicant: Imperial College Innovations LimitedInventors: Stephen Hart, Simak Ali, Boris PuFong, Andrew Porter, Laki Buluwela, Satu Vainikka, John Jenkinson, Patrick Kanda